Literature DB >> 33051749

Risk Factors Associated with Mortality Among Patients with Novel Coronavirus Disease (COVID-19) in Africa.

Mustapha Mohammed1,2, Surajuddeen Muhammad3, Fatima Zaji Mohammed4, Sagir Mustapha5,6, Abubakar Sha'aban7,8, Najib Yahaya Sani9,10, Mubarak Hussaini Ahmad6,11, Auwal Adam Bala12,13, Marzuq Abubakar Ungogo14,15, Nawaf M Alotaibi16, Hadzliana Zainal7.   

Abstract

BACKGROUND: The novel coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in China and later spread rapidly to other parts of the world, including Africa. Africa was projected to be devastated by COVID-19. There is currently limited data regarding regional predictors of mortality among patients with COVID-19. This study aimed to evaluate the independent risk factors associated with mortality among patients with COVID-19 in Africa.
METHODS: A total of 1028 confirmed cases of COVID-19 from Africa with definite survival outcomes were identified retrospectively from an open-access individual-level worldwide COVID-19 database. The live version of the dataset is available at https://github.com/beoutbreakprepared/nCoV2019 . Multivariable logistic regression was conducted to determine the risk factors that independently predict mortality among patients with COVID-19 in Africa.
RESULTS: Of the 1028 cases included in study, 432 (42.0%) were females with a median (interquartile range, IQR) age of 50 (24) years. Older age (adjusted odds ratio {aOR} 1.06; [95% confidence intervals {95% CI}, 1.04-1.08]), presence of chronic disease (aOR 9.63; [95% CI, 3.84-24.15]), travel history (aOR 2.44; [95% CI, 1.26-4.72]), as well as locations of Central Africa (aOR 0.14; [95% CI, 0.03-0.72]) and West Africa (aOR 0.12; [95% CI, 0.04-0.32]) were identified as the independent risk factors significantly associated with increased mortality among the patients with COVID-19.
CONCLUSIONS: The COVID-19 pandemic is evolving gradually in Africa. Among patients with COVID-19 in Africa, older age, presence of chronic disease, travel history, and the locations of Central Africa and West Africa were associated with increased mortality. A regional response should prioritize strategies that will protect these populations. Also, conducting a further in-depth study could provide more insights into additional factors predictive of mortality in COVID-19 patients.
© 2020. W. Montague Cobb-NMA Health Institute.

Entities:  

Keywords:  Africa; COVID-19; Mortality; Pandemic; Risk factors; SARS-COV-2

Mesh:

Year:  2020        PMID: 33051749      PMCID: PMC7553376          DOI: 10.1007/s40615-020-00888-3

Source DB:  PubMed          Journal:  J Racial Ethn Health Disparities        ISSN: 2196-8837


Introduction

Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1]. The first case of the virus was reported in Wuhan, China, in December 2019 [2, 3]. The virus has spread rapidly worldwide since its outbreak with the World Health Organization (WHO) declaring it as a pandemic [4]. As of August 25, 2020, more than 23 million cases of COVID-19 have been reported across over 215 countries/territories, resulting in more than 800 thousand deaths [5]. The global COVID-19 data showed America, Asia, and Europe to be the most hit continents with COVID-19 as compared with other continents like Africa [6]. The first confirmed case of COVID-19 in Africa was reported in Egypt on February 14, 2020 [7]. The African countries currently identified to have the highest number of cases are South Africa, Egypt, Morocco, Nigeria, and Ghana [5]. Africa is the largest, most populous continent globally, after Asia, with the youngest and most diverse population with considerable genetic, linguistic, cultural, and ethnic diversity [8-11]. Africa is also the least-developed continent, contributing about 40% of the global burden of disease [12]. The major contributors to the African disease burden include infectious diseases (HIV and AIDS, malaria), neglected tropical diseases (trypanosomiasis, leishmaniasis), diseases predominantly affecting African populations (sickle cell disease), non-communicable diseases (hypertension, diabetes), and diseases of poverty (malnutrition) [12]. These disease burdens are further complicated by limited access to safe, effective, quality, and affordable medicines. Responses to African epidemics have been threatened by insufficient infrastructure and weak healthcare systems, including lack of sufficient monitoring to determine the magnitude of the outbreak and insufficient structures to prevent, diagnose, and treat diseases [13]. There is a high reliance on traditional, complementary, and alternative medicines in Africa [11, 14]. Deficient healthcare systems in Africa have resulted in high preventable morbidity and mortality, creating a vicious cycle of poverty [15-17]. These factors, put together, led to the projections that the COVID-19 pandemic could be challenging to keep under control in Africa and could cause a substantial socioeconomic burden if allowed to spread [18]. Therefore, in this study, we described the characteristics of patients with COVID-19 in Africa and identified the various risk factors associated with COVID-19 mortality in the continent.

Methods

Study Design

The study was a retrospective cross-sectional study that involved the extraction of all confirmed cases of COVID-19 in Africa that had a definite survival outcome from the open-access individual-level COVID-19 database reported elsewhere [19]. The data were extracted on August 25, 2020. The database is a hub of updated and curated COVID-19 data generated from a range of different validated sources, including international, national, state, provincial, municipal, news reports, as well as peer-reviewed articles. A real-time updated version of the dataset is downloadable as a comma-separated value (CSV) from a GitHub repository (https://github.com/beoutbreakprepared/nCoV2019). The repository is a product of the Open COVID-19 Data Working Group: a multi-organizational global scheme that focused on enabling rapid sharing of trusted and open-access public health data in advancing the response to infectious diseases.

Data Collection

The patient characteristics collected in our study include COVID-19 diagnosis confirmation, demographic data such as age and gender, chronic disease, travel history, and survival outcomes (dead or alive). Survival (alive) was defined as those patients with outcomes labeled as “alive,” “discharge,” “discharged,” “discharged from hospital,” “recovered,” “recovering from home,” “released from quarantine,” “stable,” or “stable condition,” while mortality (dead) was defined as those patients with outcomes labeled as “dead,” “died,” “death,” or “deceased.”

Inclusion and Exclusion Criteria

We included only reported confirmed cases of COVID-19 that had a definite survival outcome (dead or alive) and from only African countries. Those confirmed cases without survival outcomes and not from any of the African countries were excluded from this study.

Statistical Analysis

The data collected in CSV format were exported into Microsoft Excel and then analyzed with IBM SPSS Version 24.0 (SPSS Inc., Chicago, IL, USA). The data were assessed for missing values, and a multiple imputation method was used to handle variables with missing data of more than 5%. Five imputations were performed and combined through Rubin’s rules. A normality test was conducted on the continuous numerical variable, age, using the histogram method and Kolmogorov-Smirnov (KS) test, and was found to be not normally distributed. The results of age were presented as median (interquartile range, IQR), while the categorical variables were presented as frequencies and percentages. The risk factors associated with mortality were determined using multivariable logistic regression (MLR). Univariable analysis was initially conducted using simple binary logistic regression (SLR) to screen each of the independent variables (age, gender, chronic disease, travel history, region) for inclusion in the multivariable analysis. From the results of SLR, variables that had a p < 0.25 and those considered relevant were included in the MLR. The MLR was performed using both the backward and forward likelihood ratio method to determine independent risk factors associated with mortality. Multicollinearity and interactions between the variables were checked. Goodness-of-fit model assumptions were checked using Hosmer-Lemeshow and Omnibus Tests of Model Coefficients. The results of the SLR were presented as a crude odds ratio (OR) with 95% confidence intervals (CIs) and corresponding p values, while the final model was presented as adjusted OR with 95% CIs and corresponding p values.

Results

Characteristics of Patients with COVID-19

A total of 1028 COVID-19 patients from Africa were found to have a definitive survival outcome. The number of female patients were 432 (42.0%), with an overall median (IQR) age of 50 (24) years. Among the patients, 32 (3.1%) had at least one chronic disease, and 210 (20.4%) had travel history. Most of the COVID-19 patients were from West Africa, 479 (46.6%), and the least were from Central Africa 89 (8.7%). From the available data, the overall number of deaths was 60 (5.6%). The details of the characteristics of patients with COVID-19 are presented in Table 1.
Table 1

Demographic and clinical characteristics of the patients with COVID-19

CharacteristicsN (%)
Age (median, IQR)50 (24)
Female gender432 (42.0)
Chronic disease32 (3.1)
Travel history210 (20.4)
African region
  North90 (8.8)
  South196 (19.1)
  Central89 (8.7)
  East174 (16.9)
  West479 (46.6)
Mortality60 (5.6)
Demographic and clinical characteristics of the patients with COVID-19

Risk Factors Associated of Mortality in Patients with COVID-19

From the univariable analysis, all the five independent variables (age, gender, chronic disease, travel history, and region) were selected for the multivariable analysis. The final model of variables associated with mortality in patients with COVID-19 showed that the predictors of the mortality were older age (aOR 1.06; [95% CI, 1.04–1.08]), presence of chronic disease (aOR 9.63; [95% CI, 3.84–24.15]), and travel history (aOR 2.44; [95% CI, 1.26–4.72]). Also, patients with COVID-19 located in Central Africa (aOR 0.14; [95% CI, 0.03–0.72]) and West Africa (aOR 0.12; [95% CI, 0.04–0.32]) were also associated with mortality. No possible collinearity in the included variables was observed and no interactions between the variables. The model fit for the data was excellent, as the Hosmer-Lemeshow test p value was 0.55. The univariate analysis and the final model were presented as ORs or adjusted ORs with 95% CIs and corresponding p values in Table 2.
Table 2

Risk factors associated with mortality in patients with COVID-19

VariableUnivariate analysisMultivariable analysis
OR (95% CI)p valueaOR (95% CI)p value
Age, years1.06 (1.04–1.08)< 0.0011.06 (1.04–1.08)< 0.001
Female gender0.99 (0.58–1.67)0.954
Chronic disease16.06 (7.52–34.30)< 0.0019.63 (3.84–24.15)< 0.001
Travel history3.78 (2.22–6.43)< 0.0012.44 (1.26–4.72)0.008
African region
  North11
  South0.15 (0.22–1.26)0.1470.38 (0.14–1.06)0.066
  Central0.18 (0.04–0.87)0.0320.14 (0.03–0.72)0.018
  East1.34 (0.61–2.93)0.4610.44 (0.16–1.18)0.103
  West0.19 (0.08–0.46)< 0.0010.12 (0.04–0.32)< 0.001

OR odds ratio, aOR adjusted odds ratio, 95% CI 95% confidence interval; classification table 94.2% correctly classified using backward stepwise (likelihood ratio) method of the logistic regression

Risk factors associated with mortality in patients with COVID-19 OR odds ratio, aOR adjusted odds ratio, 95% CI 95% confidence interval; classification table 94.2% correctly classified using backward stepwise (likelihood ratio) method of the logistic regression

Discussion

We provide in this study novel findings on the risk factors that are independently associated with mortality among 1028 patients with COVID-19 in Africa. Africa has been projected to be devastated by COVID-19 [20, 21]. It was suggested that with neither effective treatment nor vaccines, and without prior immunity, the impact of the virus might be devastating because of the health systems challenges in the continent [20]. However, the current evidence suggests that Africa is one of the least hits by COVID-19, accounting for only about 5% and 3% of the world’s cumulative cases and deaths, respectively [5]. A weak healthcare system, low socioeconomic status, healthcare-seeking, cultural and cohabitation practices, variations in immune profiles, and limited technology could be attributed to the limited impact of COVID-19 in Africa [22]. In this study, we identified the risk factors that are independently associated with mortality in patients with COVID-19 in Africa from a worldwide open-access database reported elsewhere [19]. The COVID-19 mortality rate reported previously ranged from 4 to 28% [23-28]. The lower mortality rate of 5.6% in our study is consistent with the previous studies and could be explained by the milder burden of COVID-19 in Africa. This variation in mortality rates may be due to discrepancies in healthcare systems, public health responses, and/or epidemiological characteristics of patients [29]. Other reports suggested lower contact tracing, weaker testing capacities, and poor reporting strategies in Africa could be responsible for the lower reported cases of COVID-19 [21, 30]. We identified several risk factors associated with mortality in patients with COVID-19 in Africa, including older age, chronic disease, travel history, and patients in Central and West Africa. Similar studies reported a significant increase in mortality among older COVID-19 patients in Wuhan, China [27], New York City, the USA [31], Ontario, Canada [32], Lombardy, Italy [33], and worldwide [28]. Older age has also been reported as a key independent predictor of mortality in similar diseases like SARS and MERS [34, 35]. A higher viral load was found in older patients with COVID-19 [36] and could be associated with mortality. Previous studies also found that older subjects had improved innate host responses to inoculated SARS-CoV virus than younger ones, with an increased expression of genes associated with inflammation and reduced expression of type I interferon-beta [37]. Also, the age-dependent defects in the function of cellular immunity and the overproduction of type 2 cytokines could lead to reduced control of viral replication and more prolonged proinflammatory responses, leading to poor outcomes, including death [38]. Thus, older age is associated with a weaker immune system and are more susceptible to the infections, acute respiratory distress syndrome (ARDS), and, subsequently, death. The studies on patients with COVID-19 infection have shown that those with underlying chronic diseases not only have a higher risk of developing the disease but also are more likely to die from the infection [39]. Chronic disease conditions, such as cardiovascular and metabolic diseases, were reported to be associated with severe cases of COVID-19 [40, 41]. Chronic obstructive pulmonary disease, hypercholesterolemia, obesity, and diabetes were reported to be independently associated with mortality in COVID-19 patients [26, 33]. Similarly, our study identified that the presence of underlying chronic disease conditions is independently associated with mortality in patients with COVID-19. Conversely, a study found no association between in-hospital mortality and some common coexisting medical conditions, including hypertension, diabetes, or cancer [31]. Our study reports travel history to be associated with mortality in patients with COVID-19. Several person-to-person transmission of SARS-CoV-2 have been documented in patients with travel-related COVID-19 [42]. Initially, the virus was first imported to Africa, like many other continents, with most imported cases arriving from Europe and the USA rather than from China [43]. Several preventive measures have been implemented in different countries of Africa, including restrictions on travel, flight cancelations, restrictions on mass gathering, school closures, and border closures [43]. There are ongoing concerns over the effectiveness of travel restrictions to contain the spread of COVID-19. A study found that travel restrictions had only moderately improved the initial spread of COVID-19 and could only considerably reduce transmissions if combined with other prevention and control measures [44]. This study has some limitations and should be interpreted with caution. The study was retrospective, and data utilized was from an open-access curated and validated COVID-19 data repository. Thus, the data is secondary, and other clinical and laboratory data to assess patient disease status were unavailable. Smoking status and other socioeconomic status were also lacking. The severity of the chronic conditions and compliance with medications were not documented and could not be evaluated. Furthermore, the cases and mortality may not reflect the actual percentage because only patients with definitive outcomes were included resulting in relatively smaller numbers than the real confirmed cases reported in Africa.

Conclusion

The COVID-19 pandemic continues to evolve gradually in Africa despite higher projections. We found that older age, chronic disease, travel history, and location of Central and West Africa were risk factors associated with death in patients with COVID-19 in Africa. A regional response should prioritize strategies that will protect these categories of patients. Also, conducting a further in-depth study could provide more insights into additional factors predictive of mortality in COVID-19 patients. Government intervention should ensure improved surveillance, laboratory capacity, and public health response that could further validate the findings of COVID-19 studies in Africa.
  36 in total

1.  Managing COVID-19 in Low- and Middle-Income Countries.

Authors:  Joost Hopman; Benedetta Allegranzi; Shaheen Mehtar
Journal:  JAMA       Date:  2020-04-28       Impact factor: 56.272

2.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.

Authors:  Dawei Wang; Bo Hu; Chang Hu; Fangfang Zhu; Xing Liu; Jing Zhang; Binbin Wang; Hui Xiang; Zhenshun Cheng; Yong Xiong; Yan Zhao; Yirong Li; Xinghuan Wang; Zhiyong Peng
Journal:  JAMA       Date:  2020-03-17       Impact factor: 56.272

3.  Exacerbated innate host response to SARS-CoV in aged non-human primates.

Authors:  Saskia L Smits; Anna de Lang; Judith M A van den Brand; Lonneke M Leijten; Wilfred F van IJcken; Marinus J C Eijkemans; Geert van Amerongen; Thijs Kuiken; Arno C Andeweg; Albert D M E Osterhaus; Bart L Haagmans
Journal:  PLoS Pathog       Date:  2010-02-05       Impact factor: 6.823

4.  Preparedness and vulnerability of African countries against importations of COVID-19: a modelling study.

Authors:  Marius Gilbert; Giulia Pullano; Francesco Pinotti; Eugenio Valdano; Chiara Poletto; Pierre-Yves Boëlle; Eric D'Ortenzio; Yazdan Yazdanpanah; Serge Paul Eholie; Mathias Altmann; Bernardo Gutierrez; Moritz U G Kraemer; Vittoria Colizza
Journal:  Lancet       Date:  2020-02-20       Impact factor: 79.321

5.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study.

Authors:  Nanshan Chen; Min Zhou; Xuan Dong; Jieming Qu; Fengyun Gong; Yang Han; Yang Qiu; Jingli Wang; Ying Liu; Yuan Wei; Jia'an Xia; Ting Yu; Xinxin Zhang; Li Zhang
Journal:  Lancet       Date:  2020-01-30       Impact factor: 79.321

Review 6.  COVID-19 in Egypt: Uncovered figures or a different situation?

Authors:  Mohammed A Medhat; Mohamed El Kassas
Journal:  J Glob Health       Date:  2020-06       Impact factor: 4.413

7.  First cases of coronavirus disease 2019 (COVID-19) in the WHO European Region, 24 January to 21 February 2020.

Authors:  Gianfranco Spiteri; James Fielding; Michaela Diercke; Christine Campese; Vincent Enouf; Alexandre Gaymard; Antonino Bella; Paola Sognamiglio; Maria José Sierra Moros; Antonio Nicolau Riutort; Yulia V Demina; Romain Mahieu; Markku Broas; Malin Bengnér; Silke Buda; Julia Schilling; Laurent Filleul; Agnès Lepoutre; Christine Saura; Alexandra Mailles; Daniel Levy-Bruhl; Bruno Coignard; Sibylle Bernard-Stoecklin; Sylvie Behillil; Sylvie van der Werf; Martine Valette; Bruno Lina; Flavia Riccardo; Emanuele Nicastri; Inmaculada Casas; Amparo Larrauri; Magdalena Salom Castell; Francisco Pozo; Rinat A Maksyutov; Charlotte Martin; Marc Van Ranst; Nathalie Bossuyt; Lotta Siira; Jussi Sane; Karin Tegmark-Wisell; Maria Palmérus; Eeva K Broberg; Julien Beauté; Pernille Jorgensen; Nick Bundle; Dmitriy Pereyaslov; Cornelia Adlhoch; Jukka Pukkila; Richard Pebody; Sonja Olsen; Bruno Christian Ciancio
Journal:  Euro Surveill       Date:  2020-03

8.  Understanding and Interpretation of Case Fatality Rate of Coronavirus Disease 2019.

Authors:  Dong Hyun Kim; Young June Choe; Jin Young Jeong
Journal:  J Korean Med Sci       Date:  2020-03-30       Impact factor: 2.153

9.  Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study.

Authors:  Tao Chen; Di Wu; Huilong Chen; Weiming Yan; Danlei Yang; Guang Chen; Ke Ma; Dong Xu; Haijing Yu; Hongwu Wang; Tao Wang; Wei Guo; Jia Chen; Chen Ding; Xiaoping Zhang; Jiaquan Huang; Meifang Han; Shusheng Li; Xiaoping Luo; Jianping Zhao; Qin Ning
Journal:  BMJ       Date:  2020-03-26

10.  WHO Declares COVID-19 a Pandemic.

Authors:  Domenico Cucinotta; Maurizio Vanelli
Journal:  Acta Biomed       Date:  2020-03-19
View more
  7 in total

1.  Generalizable prediction of COVID-19 mortality on worldwide patient data.

Authors:  Maxim Edelson; Tsung-Ting Kuo
Journal:  JAMIA Open       Date:  2022-05-25

2.  COVID-19 Awareness, Adoption of COVID-19 Preventive Measures, and Effects of COVID-19 Lockdown Among Adolescent Boys and Young Men in Kampala, Uganda.

Authors:  Joseph K B Matovu; Stephen N Kabwama; Tonny Ssekamatte; John Ssenkusu; Rhoda K Wanyenze
Journal:  J Community Health       Date:  2021-01-22

3.  Clinical features and predictors of mortality among hospitalized patients with COVID-19 in Niger.

Authors:  Patrick D M C Katoto; Issoufou Aboubacar; Batouré Oumarou; Eric Adehossi; Blanche-Philomene Melanga Anya; Aida Mounkaila; Adamou Moustapha; El Khalef Ishagh; Gbaguidi Aichatou Diawara; Biey Joseph Nsiari-Muzeyi; Tambwe Didier; Charles Shey Wiysonge
Journal:  Confl Health       Date:  2021-12-14       Impact factor: 2.723

4.  Factors associated with acceptance of COVID-19 vaccine among University health sciences students in Northwest Nigeria.

Authors:  Mohammed Mustapha; Basira Kankia Lawal; Abubakar Sha'aban; Abubakar Ibrahim Jatau; Abubakar Sadiq Wada; Auwal Adam Bala; Sagir Mustapha; Anas Haruna; Abbas Musa; Mubarak Hussaini Ahmad; Salim Iliyasu; Surajuddeen Muhammad; Fatima Zaji Mohammed; Ahmed Danbala Ahmed; Hadzliana Zainal
Journal:  PLoS One       Date:  2021-11-29       Impact factor: 3.240

5.  Clinical Characteristics and Treatment Outcomes of COVID-19 Patients at Eka Kotebe General Hospital, Addis Ababa, Ethiopia.

Authors:  Dawit Kebede Huluka; Eyob Kebede Etissa; Sebrina Ahmed; Hiluf Abate; Nebiyu Getachew; Sisay Abera; Abebaw Bekele; Hiruy Araya; Tsegaye Gebreyes; Bethelehem Tadesse; Getachew Demoz; Yonas Gebreegziabher; Rediet Yitagesu; Addisu Berhanu; Yohannes Feleke; Yonathan Abebe; Tewodros Haile; Hanan Yusuf; Wondwossen Amogne; Deborah A Haisch; Charles B Sherman; Neil W Schluger
Journal:  Am J Trop Med Hyg       Date:  2022-07-05       Impact factor: 3.707

Review 6.  The Management of Myocardial Injury Related to SARS-CoV-2 Pneumonia.

Authors:  Mohammed Ahmed Akkaif; Ahmad Naoras Bitar; Laith A I K Al-Kaif; Nur Aizati Athirah Daud; Abubakar Sha'aban; Dzul Azri Mohamed Noor; Fatimatuzzahra' Abd Aziz; Arturo Cesaro; Muhamad Ali Sk Abdul Kader; Mohamed Jahangir Abdul Wahab; Chee Sin Khaw; Baharudin Ibrahim
Journal:  J Cardiovasc Dev Dis       Date:  2022-09-16

7.  Multiple introduced lineages and the single native lineage co-driving the four waves of the COVID-19 pandemic in West Africa.

Authors:  Liping Gao; Canjun Zheng; Qi Shi; Lili Wang; Alie Tia; Jone Ngobeh; Zhiguo Liu; Xiaoping Dong; Zhenjun Li
Journal:  Front Public Health       Date:  2022-09-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.